

IBS-C Drugs-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/I8E4E437068MEN.html

Date: May 2018

Pages: 148

Price: US\$ 2,480.00 (Single User License)

ID: I8E4E437068MEN

Abstracts

Report Summary

IBS-C Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of IBS-C Drugs worldwide, with company and product introduction, position in the IBS-C Drugs market

Market status and development trend of IBS-C Drugs by types and applications Cost and profit status of IBS-C Drugs, and marketing status Market growth drivers and challenges

The report segments the global IBS-C Drugs market as:

Global IBS-C Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America

Europe

China

Japan

Rest APAC



Latin America

Global IBS-C Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other

Global IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Pharmacies Retail Pharmacies Online Pharmacies

Global IBS-C Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):

Catalent Pharmaceuticals Solutions

Nestle

Abbott Laboratories

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Novartis Pharma Ag

Astellas Pharmaceuticals

Ardelyx, Inc

Synthetic Biologics, Inc.

Teva Pharmaceutical Industries

Bama-Geve, SLU

Ferring BV

Ironwood Pharmaceuticals, Inc.

Salix Pharmaceuticals Ltd

Norgine B.V

Prometheus Laboratories Inc

Actavis Nordic A/S

Albireo Pharma Inc



Yuhan Corp Astrazeneca Plc The Menarini Group Ono Pharmaceutical Co., Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF IBS-C DRUGS

- 1.1 Definition of IBS-C Drugs in This Report
- 1.2 Commercial Types of IBS-C Drugs
 - 1.2.1 Linaclotide
 - 1.2.2 Lubiprostone
 - 1.2.3 Osmotic Laxatives
 - 1.2.4 Stimulant Laxatives
 - 1.2.5 Other
- 1.3 Downstream Application of IBS-C Drugs
 - 1.3.1 Hospital Pharmacies
 - 1.3.2 Retail Pharmacies
 - 1.3.3 Online Pharmacies
- 1.4 Development History of IBS-C Drugs
- 1.5 Market Status and Trend of IBS-C Drugs 2013-2023
 - 1.5.1 Global IBS-C Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of IBS-C Drugs 2013-2017
- 2.2 Sales Market of IBS-C Drugs by Regions
- 2.2.1 Sales Volume of IBS-C Drugs by Regions
- 2.2.2 Sales Value of IBS-C Drugs by Regions
- 2.3 Production Market of IBS-C Drugs by Regions
- 2.4 Global Market Forecast of IBS-C Drugs 2018-2023
 - 2.4.1 Global Market Forecast of IBS-C Drugs 2018-2023
 - 2.4.2 Market Forecast of IBS-C Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of IBS-C Drugs by Types
- 3.2 Sales Value of IBS-C Drugs by Types
- 3.3 Market Forecast of IBS-C Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY



- 4.1 Global Sales Volume of IBS-C Drugs by Downstream Industry
- 4.2 Global Market Forecast of IBS-C Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America IBS-C Drugs Market Status by Countries
 - 5.1.1 North America IBS-C Drugs Sales by Countries (2013-2017)
 - 5.1.2 North America IBS-C Drugs Revenue by Countries (2013-2017)
 - 5.1.3 United States IBS-C Drugs Market Status (2013-2017)
 - 5.1.4 Canada IBS-C Drugs Market Status (2013-2017)
 - 5.1.5 Mexico IBS-C Drugs Market Status (2013-2017)
- 5.2 North America IBS-C Drugs Market Status by Manufacturers
- 5.3 North America IBS-C Drugs Market Status by Type (2013-2017)
 - 5.3.1 North America IBS-C Drugs Sales by Type (2013-2017)
 - 5.3.2 North America IBS-C Drugs Revenue by Type (2013-2017)
- 5.4 North America IBS-C Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe IBS-C Drugs Market Status by Countries
 - 6.1.1 Europe IBS-C Drugs Sales by Countries (2013-2017)
 - 6.1.2 Europe IBS-C Drugs Revenue by Countries (2013-2017)
 - 6.1.3 Germany IBS-C Drugs Market Status (2013-2017)
 - 6.1.4 UK IBS-C Drugs Market Status (2013-2017)
 - 6.1.5 France IBS-C Drugs Market Status (2013-2017)
 - 6.1.6 Italy IBS-C Drugs Market Status (2013-2017)
 - 6.1.7 Russia IBS-C Drugs Market Status (2013-2017)
 - 6.1.8 Spain IBS-C Drugs Market Status (2013-2017)
 - 6.1.9 Benelux IBS-C Drugs Market Status (2013-2017)
- 6.2 Europe IBS-C Drugs Market Status by Manufacturers
- 6.3 Europe IBS-C Drugs Market Status by Type (2013-2017)
 - 6.3.1 Europe IBS-C Drugs Sales by Type (2013-2017)
 - 6.3.2 Europe IBS-C Drugs Revenue by Type (2013-2017)
- 6.4 Europe IBS-C Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,



MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific IBS-C Drugs Market Status by Countries
 - 7.1.1 Asia Pacific IBS-C Drugs Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific IBS-C Drugs Revenue by Countries (2013-2017)
 - 7.1.3 China IBS-C Drugs Market Status (2013-2017)
 - 7.1.4 Japan IBS-C Drugs Market Status (2013-2017)
 - 7.1.5 India IBS-C Drugs Market Status (2013-2017)
 - 7.1.6 Southeast Asia IBS-C Drugs Market Status (2013-2017)
 - 7.1.7 Australia IBS-C Drugs Market Status (2013-2017)
- 7.2 Asia Pacific IBS-C Drugs Market Status by Manufacturers
- 7.3 Asia Pacific IBS-C Drugs Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific IBS-C Drugs Sales by Type (2013-2017)
- 7.3.2 Asia Pacific IBS-C Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific IBS-C Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America IBS-C Drugs Market Status by Countries
 - 8.1.1 Latin America IBS-C Drugs Sales by Countries (2013-2017)
 - 8.1.2 Latin America IBS-C Drugs Revenue by Countries (2013-2017)
 - 8.1.3 Brazil IBS-C Drugs Market Status (2013-2017)
 - 8.1.4 Argentina IBS-C Drugs Market Status (2013-2017)
 - 8.1.5 Colombia IBS-C Drugs Market Status (2013-2017)
- 8.2 Latin America IBS-C Drugs Market Status by Manufacturers
- 8.3 Latin America IBS-C Drugs Market Status by Type (2013-2017)
 - 8.3.1 Latin America IBS-C Drugs Sales by Type (2013-2017)
 - 8.3.2 Latin America IBS-C Drugs Revenue by Type (2013-2017)
- 8.4 Latin America IBS-C Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa IBS-C Drugs Market Status by Countries
 - 9.1.1 Middle East and Africa IBS-C Drugs Sales by Countries (2013-2017)
 - 9.1.2 Middle East and Africa IBS-C Drugs Revenue by Countries (2013-2017)
 - 9.1.3 Middle East IBS-C Drugs Market Status (2013-2017)
 - 9.1.4 Africa IBS-C Drugs Market Status (2013-2017)



- 9.2 Middle East and Africa IBS-C Drugs Market Status by Manufacturers
- 9.3 Middle East and Africa IBS-C Drugs Market Status by Type (2013-2017)
 - 9.3.1 Middle East and Africa IBS-C Drugs Sales by Type (2013-2017)
- 9.3.2 Middle East and Africa IBS-C Drugs Revenue by Type (2013-2017)
- 9.4 Middle East and Africa IBS-C Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS

- 10.1 Global Economy Situation and Trend Overview
- 10.2 IBS-C Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 11.1 Production Volume of IBS-C Drugs by Major Manufacturers
- 11.2 Production Value of IBS-C Drugs by Major Manufacturers
- 11.3 Basic Information of IBS-C Drugs by Major Manufacturers
- 11.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Manufacturer
 - 11.3.2 Employees and Revenue Level of IBS-C Drugs Major Manufacturer
- 11.4 Market Competition News and Trend
 - 11.4.1 Merger, Consolidation or Acquisition News
 - 11.4.2 Investment or Disinvestment News
 - 11.4.3 New Product Development and Launch

CHAPTER 12 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 12.1 Catalent Pharmaceuticals Solutions
 - 12.1.1 Company profile
 - 12.1.2 Representative IBS-C Drugs Product
- 12.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions
- 12.2 Nestle
 - 12.2.1 Company profile
 - 12.2.2 Representative IBS-C Drugs Product
 - 12.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
- 12.3 Abbott Laboratories



- 12.3.1 Company profile
- 12.3.2 Representative IBS-C Drugs Product
- 12.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 12.4 Synergy Pharmaceuticals
 - 12.4.1 Company profile
 - 12.4.2 Representative IBS-C Drugs Product
 - 12.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy

Pharmaceuticals

- 12.5 Sucampo Pharmaceuticals
 - 12.5.1 Company profile
- 12.5.2 Representative IBS-C Drugs Product
- 12.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo

Pharmaceuticals

- 12.6 Novartis Pharma Ag
 - 12.6.1 Company profile
 - 12.6.2 Representative IBS-C Drugs Product
 - 12.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
- 12.7 Astellas Pharmaceuticals
 - 12.7.1 Company profile
 - 12.7.2 Representative IBS-C Drugs Product
 - 12.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas

Pharmaceuticals

- 12.8 Ardelyx, Inc
 - 12.8.1 Company profile
 - 12.8.2 Representative IBS-C Drugs Product
 - 12.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
- 12.9 Synthetic Biologics, Inc
 - 12.9.1 Company profile
 - 12.9.2 Representative IBS-C Drugs Product
- 12.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics,

Inc

- 12.10 Teva Pharmaceutical Industries
 - 12.10.1 Company profile
- 12.10.2 Representative IBS-C Drugs Product
- 12.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
- 12.11 Bama-Geve, SLU
 - 12.11.1 Company profile
 - 12.11.2 Representative IBS-C Drugs Product



- 12.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
- 12.12 Ferring BV
 - 12.12.1 Company profile
- 12.12.2 Representative IBS-C Drugs Product
- 12.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
- 12.13 Ironwood Pharmaceuticals, Inc.
 - 12.13.1 Company profile
 - 12.13.2 Representative IBS-C Drugs Product
 - 12.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood

Pharmaceuticals, Inc.

- 12.14 Salix Pharmaceuticals Ltd
 - 12.14.1 Company profile
 - 12.14.2 Representative IBS-C Drugs Product
 - 12.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix

Pharmaceuticals Ltd

- 12.15 Norgine B.V
 - 12.15.1 Company profile
 - 12.15.2 Representative IBS-C Drugs Product
 - 12.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
- 12.16 Prometheus Laboratories Inc
- 12.17 Actavis Nordic A/S
- 12.18 Albireo Pharma Inc
- 12.19 Yuhan Corp
- 12.20 Astrazeneca Plc
- 12.21 The Menarini Group
- 12.22 Ono Pharmaceutical Co., Ltd

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS

- 13.1 Industry Chain of IBS-C Drugs
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS

- 14.1 Cost Structure Analysis of IBS-C Drugs
- 14.2 Raw Materials Cost Analysis of IBS-C Drugs
- 14.3 Labor Cost Analysis of IBS-C Drugs



14.4 Manufacturing Expenses Analysis of IBS-C Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference



I would like to order

Product name: IBS-C Drugs-Global Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/l8E4E437068MEN.html

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l8E4E437068MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms